Structure-Activity Analysis of Peptidic Chlamydia HtrA Inhibitors by Tyndall, Joel et al.
1 
 
Structure-Activity Analysis of Peptidic Chlamydia HtrA 
Inhibitors 
Ayodeji A. Agbowuro,a Jimin Hwang,a Emma Peel,b Rami Mazraani,c Alexandra 
Springwald,a James W. Marsh,d Laura McCaughey,d,e Allan B. Gamble,a 
Wilhelmina M. Huston,*,c Joel D. A. Tyndall*,a 
a School of Pharmacy, University of Otago, Dunedin, 9054, New Zealand 
b School of Life and Environmental Sciences, The University Sydney, Sydney, NSW 2006, 
Australia 
c School of Life Sciences, University of Technology Sydney, 15 Broadway, Ultimo NSW 2007, 
Australia 
d The iThree Institute, University of Technology Sydney, 15 Broadway, Ultimo NSW 2007, 
Australia 
e Department of Biochemistry, University of Oxford, South Park road, Oxford OX1 3QU, United 
Kingdom 





ABSTRACT: Chlamydia trachomatis high temperature requirement A (CtHtrA) is a serine 
protease that performs proteolytic and chaperone functions in pathogenic Chlamydiae; and 
is seen as a prospective drug target. This study details the strategies employed in optimizing 
the irreversible CtHtrA inhibitor JO146 [Boc-Val-Pro-ValP(OPh)2] for potency and 
selectivity. A series of adaptations both at the warhead and specificity residues P1 and P3 
yielded 23 analogues, which were tested in human neutrophil elastase (HNE) and CtHtrA 
enzyme assays as well as Chlamydia cell culture assays. Trypsin and chymotrypsin 
inhibition assays were also conducted to measure off-target selectivity. Replacing the 
phosphonate moiety with α-ketobenzothiazole produced a reversible analogue with 
considerable CtHtrA inhibition and cell culture activity. Tertiary leucine at P3 (8a) yielded 
approximately 33-fold increase in CtHtrA inhibitory activity, with an IC50 = 0.68 ± 0.02 
µM against HNE, while valine at P1 retained the best anti-chlamydial activity. This study 






Members of the phylum Chlamydiae are a unique obligate intracellular bacteria, responsible for a 
host of diseases with the most notable being Chlamydia (C.) trachomatis and C. pneumoniae.1-2 
C. trachomatis parasitizes only humans, causing complications including ectopic pregnancy, 
infertility, reversible blindness and infant pneumonia.3-4 C. pneumoniae is the major cause of 
respiratory infections in children and adults, leading to pneumonia, bronchitis, sinusitis, and it is 
also a risk factor for atherosclerosis.5-6 C. pneumoniae infects other animals including koalas and 
horses. 
The koala is an iconic Australian marsupial currently listed as vulnerable, with the potential for 
extinction. It is often plagued by illnesses as a result of C. pneumoniae and C. pecorum infections.7-
8 C. pecorum causes distressing ocular and urogenital site infections in the animal,8 while the (less 
frequently observed) clinical outcomes of C. pneumoniae infection in koala are respiratory in 
nature and characterized by coughing, sneezing and purulent discharge.9 
Despite the availability of efficacious antibacterial agents, the management of chlamydiosis 
remains a challenge. Human chlamydia infections are estimated to have a global incidence of 
approximately 130 million10 and clinical treatment failures have been reported11-12 leading to 
concern over the effectiveness of current treatment regimens. C. trachomatis is often present as a 
co-infection (e.g. with Neisseria gonorrhoeae or Mycoplasma genitalium) and in these pathogens, 
resistance to the commonly used anti-chlamydial therapies (macrolides, tetracyclines) is 
increasingly common, 13-15 hence a drug targeted to Chlamydia may reduce the selection of 
antibiotic resistance in the other pathogens. 
We have previously identified the C. trachomatis high temperature requirement A (CtHtrA) protein 
as a serine protease that is expressed at elevated levels under Chlamydia stress conditions, which 
possesses both proteolytic and chaperone capabilities.16 CtHtrA substrate-specificity studies 
4 
 
revealed a preference for hydrophobic amino acid residues at prime and nonprime positions, with 
a preference for small hydrophobic residues such as valine (Val) at P1, giving the enzyme an 
elastase-like specificity.17 
We have previously demonstrated that CtHtrA is essential for Chlamydia survival using two 
selective irreversible CtHtrA inhibitors, JO146 1 [Boc-Val-Pro-ValP(OPh)2; IC50 = 12.5 µM] and 
JCP83 2 [Boc-Ala-Pro-ValP(OPh)2; IC50 = 47.19 µM; Figure 1] in in vivo
18 and ex vivo19 chlamydia 
models. JO146 was also found to be active against koala Chlamydia species (C. pecorum and C. 
pneumoniae) with negligible toxicity on koala tissue19 thus validating CtHtrA as a viable drug 
target for the development of novel anti-chlamydial drugs. 
 
Figure 1. Structures of JO146 (1) and JCP83 (2) and the P3-P1 protease nomenclature.
18 TSA – 
Transition State Analogue. 
JO146 (1, IC50 = 12.5 µM)
18 is a suitable lead molecule for developing a clinically relevant protease 
inhibitor for targeting Chlamydia. However, it is currently not potent enough, and may be 
susceptible to chemical and enzymatic degradation due to its peptidic nature. This paper details 
the strategies employed in optimizing the potency and selectivity of JO146 (1). Herein, we describe 
the design, syntheses and structure activity relationships (SAR) of 23 analogues of JO146 (1) tested 
against both human and koala Chlamydia species. The compounds span a series of diphenyl 
phosphonates as well as reversible transition state analogues; namely α-ketoheterocycles, α-
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diketones, N-methylamides, valinol, α-ketoamide, and boronic acid. In addition, the P1 and P3 
valine residues of JO146 (1) were systematically replaced with other natural and non-natural amino 
acids with the aim of optimizing binding at the respective subpockets of CtHtrA.  
2. Results and discussion 
2.1 Development of new CtHtrA inhibitors 
The syntheses of targeted tripeptide inhibitors containing various transition state analogues are 
described in Schemes 1-3, S1 and S2. The diphenyl phosphonates JO146 (1) and 8a-h (Table1) 
were synthesized in order to identify the optimal subsite specificity for P3 and P1. Compounds 1, 
8a-h were synthesized according to the procedure reported by Winiarski et al.20 Cbz-protected P1 
precursors 5a-d were synthesised via an α-amidoalkylation-type reaction using the appropriate 
alkyl aldehyde 4a-d. They were subsequently deprotected to yield the hydrobromide salts 6a-d 
using 33% HBr in acetic acid. The final compounds (1, 8a-h) were obtained by coupling 6a-d to 
pre-synthesized dipeptide precursors 7a-d in an HBTU-promoted solution phase peptide coupling. 
The products were obtained as diastereomeric mixtures and biologically evaluated as such. 
Table 1. Peptidyl diphenyl phosphonate inhibitors of the form Boc-P3-Pro-P1-(OPh)2 
 
 P3 P1 
JO146 (1) Val Val 
2 Ala Val 
8a Tle Val 
8b Nva Val 
8c Ile Val 
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8d Val Ile 
8e Val Nva 
8f Val Tle 
8g Ile Ile 
8h Tle Ile 
*A derivative of 1 with Leu at P1 has previously shown no inhibition (data not shown)  
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Scheme 1. Synthesis of the peptidyl diphenyl phosphonates (8a-h)a  
 
aReagents and conditions: (a) Benzylcarbamate, 4a-d, 80-90 °C, 2 h, 15-72%; (b) 33% HBr/AcOH, 
25 °C, 2 h, 92-98%; (c) HBTU, DIEA, DMF, 25 °C, 20 h, 25-77%. 
 
The potential risk of toxicity associated with irreversible inhibition via the diphenyl phosphonate 
group in JO146 led to the decision to investigate reversible transition state analogues as 
alternatives. This entailed an exchange of the phosphonate moiety with less reactive groups 
including α-ketoheterocycles (α-ketothiazole, α-ketobenzothiazole and α-keto-N-methyl 
imidazole), α-diketones, α-ketoamide, boronic acid, and non-reactive N-alkyl methylamides and 
valinol derivatives. 
Potent peptidyl α-ketoheterocycle inhibitors of the human neutrophil elastase (HNE) as well as 
thrombin have been reported.20-21 They possess the ability to form reversible covalent bonds as 
well as making key interactions with the enzyme active site around P1'. Peptidyl α-ketoheterocycles 
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14a-e (Table 2), were prepared via Weinreb amides 13a-e by first coupling the tripeptides 11a-e to 
N,O-dimethyl-hydroxylamine hydrochloride 12 using HBTU as the reagent (Scheme 2). This was 
followed by reacting 13a-e with the respective lithiated heterocycles. The final products 14a-e 
were obtained as isomeric mixtures, characterized by additional peaks in the 1H and 13C NMR 
spectra and two distinct peaks in the HPLC trace (see SI), and were likely the result of an n-
butyllithium-induced epimerization at the alpha-carbon (relative to the heterocycle).  
Table 2. Peptidyl α-ketoheterocycle inhibitors 
Compound P3 P1 Heterocycle 
14a Val Val Thiazole 
14b Val Nva Thiazole 
14c Val Val Benzothiazole 
14d Tle Ile Benzothiazole 




Scheme 2. Synthesis of the peptidyl α-ketoheterocycles 14a-ea  
  
aReagents and conditions: (a) HBTU, DIEA, DMF, 25 °C, 20 h, 45-54%; (b) LiOH.H2O, THF, 
H2O, 25 °C, 2 h, 78-90%; (c) HBTU, DIEA, DMF, 25 °C, 20 h, 28-63%; (d) heterocycle, n-BuLi, 
THF, -78 °C, 28-54%. P3 = Val or Tle; P1 = Val, Nva or Ile 
 
Compounds with a 1,2-dicarbonyl moiety such as α-ketoamides and α-diketones, are very good 
serine traps and have been incorporated in potent and safe hepatitis C NS3 protease inhibitors used 
clinically.22-24 Previous studies into CtHtrA specificity suggest a preference for hydrophobic 
residues at P1',
16-17 identifying glycine and isoleucine as the most favored residues. In the present 
study, we utilized the ability of α-diketones to interact reversibly with the S1' pocket of CtHtrA and 
the α-diketones 18a-c were synthesized with methyl, ethyl and cyclopropyl substituents at P1'. The 
synthesis of compounds in the α-diketone series (Scheme 3) was conducted as reported by Han et 
al.22 The aldehyde 15 was generated according to the method described by Dekhane and Dodd.25 
A solution of the Weinreb amide 13a in THF was treated with LiAlH4 under nitrogen, which 
formed a stable metal complex, restricting further hydride addition that otherwise produces the 
unwanted alcohol product. Upon a mild acidic workup, the complex dissociated, yielding the 
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desired aldehyde 15. After column purification, 15 was recovered as a diastereomeric mixture, as 
indicated by the additional peaks in the 1H and 13C NMR spectra. Peptide aldehydes are reported 
to epimerize during purification, and this occurs irrespective of the purification method 
employed.26 Compound 15 was then used as the starting material for the synthesis of the 1,2-diols 
17a-c by pinacol cross coupling of 15 with the aliphatic aldehydes 16a-c as reported by 
Freudenberger et al.27 Oxidation of the 1,2-diols with Dess-Martin periodinane (DMP) afforded 
the peptidyl α-diketones 18a-c. Compounds 17a-c and 18a-c were all obtained as diastereomeric 




Scheme 3. Synthesis of the peptidyl α-diketones (18a-c)a 
 
aReagents and conditions: (a) LiAlH4, THF, -30 °C, 1 h, 83%; (b) VCl3(THF)3, Zn, DCM, 25 °C, 
2 h, 36-56%; (c) Dess-Martin periodinane (DMP), DCM, 25 °C, 20 min, 20-67%. 
The peptidic N-methylamides 24a-d, and the valinol derivative 28 were synthesized as 
noncovalent binders of CtHtrA. Compounds 24a-d were specifically designed with methyl, ethyl, 
cyclopropyl and allyl side chains for exploring P1'. The N-methylamide series (24a-d) were 
synthesized as outlined in Scheme S1 with a view to rapidly explore P1'. The N-alkylamide 
precursors, 22a-d were prepared by coupling Boc-L-valine 19 to the appropriate N-methylamine 
hydrochloride 21a-d via HATU-promoted amide coupling. Compounds 22a-d were then subjected 
to Boc deprotection using TFA, followed by treatment with 10% KOH solution to liberate the free 
amines 23a-d. Finally, 24a-d were obtained by coupling 23a-d to the pre-synthesized dipeptide 7a 
using HBTU. Conformational isomerization about the amide bond in the N-methyl amide series 
24a-d was observed by NMR spectroscopy, thus purity of the final compounds was confirmed by 
HPLC (see SI).  
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The peptidic valinol derivative 28 was also synthesized as a replacement for the phosphonate 
moiety (Scheme S2). Benzyl protected L-valinol 26 was coupled to 7a using HBTU to afford 27, 
which was converted to the final compound 28 by hydrogenolysis using Pd catalysis. In CDCl3, 
compound 28 was observed as an isomeric mixture, with additional 1H and 13C NMR peaks evident 
in the spectra. However, HPLC analysis revealed only a single peak at tr = 32.5 min, indicative of 
a conformation isomer, and not diastereomers. 
Compounds 29 and 30 with a boronic acid and α-ketoamide transition state analogue respectively 
(both present in protease inhibitors used clinically) were purchased and tested to investigate their 
applicability in this system.28-29 
2.2 Enzyme inhibition and anti-chlamydial activity 
We set out to optimize the binding affinity of the inhibitor at the nonprime positions of JO146 by 
stepwise replacement of the P1 and P3 valine residues (Table 1) with norvaline (Nva), isoleucine 
and tertiary leucine (Tle). Compounds 8a-f, 14a-c, and 18a-c were thus synthesized and tested for 
their biological activity. A bio-assessment of the compounds was conducted via protease inhibition 
assays initially against human neutrophil elastase (HNE) and CtHtrA along with off-target 
assessment carried out against the human proteases trypsin and chymotrypsin (Table 3). HNE 
possesses a similar substrate specificity to CtHtrA where substrates consist of mainly small 
hydrophobic residues such as valine and alanine, particularly at P1. Activity against HNE provides 
a good prediction for anti-CtHtrA activity and this was used as an indicator of CtHtrA activity.30-
31 The in vitro susceptibility of C. trachomatis and koala C. pecorum isolates to all compounds 
was measured by their ability to significantly reduce the pathogens’ infectious progeny, measured 
as inclusion forming units (IFU/mL; Table 3; Figures 2 and 3).  
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Table 3 CtHtrA Inhibitory activity and selectivity assessment  
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aCompounds differed from 1 by varying either the P3, P1 residue, the transition state analogue or a combination thereof. 
bC. trachomatis 
susceptibility to inhibitors at a dose of 100 µM, 16 h PI.  NA = not active in CtHtrA assay (see table S3 for details). ND = not determined, 





2.3 P3-P1 optimization 
P3 Optimization: Replacing valine with norvaline at P3 (8b) showed better activity at HNE (IC50 
= 0.45 ± 0.09 µM; JO146 IC50 = 0.83 ± 0.01 µM) but reduced both CtHtrA (9.34 × less active, 
Table 3) and cellular activity (C. trachomatis), with approximately 103.5 IFU reduction compared 
with JO146 (1) at 100 µM (Figure 2). Isoleucine at P3 (8c) was more potent against HNE IC50 = 
0.40 ± 0.03 µM) and approximately fourteen times more active than JO146 (1) (CtHtrA relative 
inhibition; Table 3), but with less cellular activity (C. trachomatis) causing a reduction in IFU/mL 
of 102 at 100 µM (Figure 2). Compound 8a with tertiary leucine at P3 showed improved HNE 
activity (IC50 = 0.68 ± 0.02 µM) over JO146 (1) and was the most active P3-optimized analogue 
yielding a 33-fold increase in relative CtHtrA inhibition compared to JO146 (1) (Table 3). The 
cellular potencies of JO146 (1) and 8a were comparable (Figure 2).  
C. pecorum displayed greater susceptibility to P3-optimized compounds 8a and 8c compared to C. 
trachomatis. Against C. pecorum, 8a remained the most active analogue with approximately 104 
reduction in IFU counts at 100 µM relative to the DMSO control. Similarly, 8c produced a 
substantial reduction in IFU counts, accounting for 103 loss of infectious progeny at 100 µM. 
However, compound 8b with norvaline at P3 showed only marginal activity against C. pecorum at 





Figure 2 C. trachomatis susceptibility to representative inhibitors (100 µM, 16 h PI) of different 
covalent and noncovalent transition state analogues during mid-replicative phase of the pathogen’s 
developmental cycle. Inclusion forming units counts (IFU/mL) were determined upon completion 
of developmental cycle. Green (P3 variants); brown (P1 variants); purple (α-ketoheterocyclic 
variants); beige (α-diketone variants); light blue and lilac (P3 and P1 variants); grey (P3 and P1 α-
ketoheterocycle). Error bars indicate the standard error of the mean obtained from experimental 
replicates (minimum of 5).*Note in this assay 103 is the threshold for detection and can be 
equivalent to too few to accurately quantify. 
 
2.4 P1 Optimization: Of the compounds synthesized for P1 optimization, the analogue with 
isoleucine at P1 (8d) showed potent HNE activity (IC50 = 0.36 ± 0.02 µM) and produced the highest 
CtHtrA relative inhibition; exhibiting twenty-fold increase in potency compared to JO146 (1,Table 
3). However, this activity was not extended to the cellular assays of the molecule at C. trachomatis 
(Figure 2), as it only produced approximately 103 loss in infectious progeny at 100 µM, which was 
less potent than JO146 (1). In addition, it also showed chymotrypsin inhibition (IC50 = 38.45 ± 
0.51 µM) which is not surprising due to the preference of chymotrypsin for larger hydrophobic 
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residues such as isoleucine at P1.
32
 The replacement of valine at P1 with norvaline (8e) and tertiary 
leucine (8f), on the other hand, was completely devoid of any CtHtrA inhibition activity and the 
latter also failed to inhibit HNE (Table 3). However, both 8e and 8f displayed promising cellular 
activity at 100 µM. Compound 8f produced ~102.5 reduction in inclusion forming units (IFU) 
counts against C. trachomatis while 8e yielded approximately 101.5 reduction in IFU counts 
relative to the untreated DMSO control (Figure 2). C. pecorum was generally less susceptible to 
compounds with P1 modification, yielding appreciably lower reduction in IFU counts for all three 
compounds relative to their activity against C. trachomatis. Although 8e produced a surprising 103 
reduction in C. pecorum IFU counts at 100 µM (Figure 3), against the 101.5 reduction recorded at 
C. trachomatis (Figure 2). The lack of in vitro CtHtrA activity by 8e and 8f but with both molecules 
displaying considerable cellular activity, suggests they may act via a different mechanism of 
action.  
 
Figure 3: Susceptibility of C. pecorum to CtHtrA inhibitors (100 µM; 16 h PI) during mid-
replicative phase of the pathogen’s developmental cycle. Infectious yield counts (IFU/mL) were 
determined upon completion of developmental cycle. Colours the same as above in Figure 2. Error 
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bars indicate the standard error of the mean obtained from experimental replicates (minimum of 
5). 
 
2.5 Replacement of Diphenylphosphonate  
The effects of substituting the phosphonate moiety in JO146 (1) with reversible analogues were 
evaluated by testing compounds 14a-e, 18a-c, 24a-d, and 28-30 for in vitro CtHtrA and HNE 
inhibition, and trypsin and chymotrypsin to assess off-target selectivity (Table 3).  
Among the reversible derivatives of JO146 (1), only the benzothiazole α-ketoheterocycle transition 
state analogue (14c) showed viable anti-chlamydial activity when simply replacing the diphenyl 
phosphonate group. The compound displayed CtHtrA relative inhibition comparable or slightly 
better than JO146 (1, 1.06 × more active; Table 3) It was less active at the closely related HNE 
(IC50 = 2.60 ± 0.15 µM; JO146 (IC50 = 0.83 ± 0.01)) implying improved selectivity over HNE 
which is desirable. The inhibitor produced some cellular activity against C. trachomatis. Against 
C. pecorum it produced a considerably greater reduction with approximately 4 log loss of 
infectious bodies at 100 µM (Figure 3). The lack of anti-chlamydial activity displayed by the 
thiazole (14a) and N-methyl imidazole (14e; data not shown) derivatives, is traceable to their 
inability to sufficiently activate the ketone carbonyl carbon towards a nucleophilic attack by the 
catalytic Ser247 of CtHtrA. These results align with previous studies by Edwards et al.
33 which 
identified peptidyl ketoheterocycle HNE inhibitors with imidazoles as incapable of forming a 
covalent adduct and supports the necessity of a covalent interaction between the inhibitor and the 
active site of CtHtrA for anti-chlamydial activity. 
To understand the structural basis for the activity exhibited by the 14c benzothiazole α-
ketoheterocycle compared to 14a, both molecules were docked into a homology model of CtHtrA. 
21 
 
The docking results (Figure 4) revealed more interaction between the benzothiazole moiety of 14c 
and the S1' pocket of CtHtrA, with the heterocycle engaging in van der Waals interactions with 
Val125 and Val144 that line the walls of the pocket, as well as a potential edge-to-face pi-stacking 
interaction with His143. Compound 14a lacks the benzene extension and is therefore unable to 
make these interactions. Any possible hydrogen bonding between the heterocyclic (thiazole) 
nitrogen and the catalytic His143 of CtHtrA was revealed to be unfavourable, as the orientation of 
the imidazole ring of His143 relative to the inhibitor thiazole ring makes it unlikely for hydrogen 
bonding to occur. This may also contribute to the difference in the anti-chlamydial activity between 
compounds 14a and 14c.  
 
Figure 4. Binding poses of 14c, magenta (A) and 14a, cyan (B) to CtHtrA (transparent surface). 
Oxygen is shown in red, nitrogen blue and sulphur in yellow. 
2.6 P1' Optimization: In addition to replacing the phosphonate group, expansion and optimization 
of P1' could be probed using α-diketone based inhibitors. Three inhibitors were synthesized (18a-
c) containing a methyl, ethyl or cyclopropyl group at P1’and showed no CtHtrA inhibition or 
cellular activity (Table 3; Figures 2 and 3). This result is surprising given both 18a and 18b showed 
inhibition against HNE albeit modest (IC50 = 1.35 ± 0.17 and IC50 = 4.71 ± 0.66 µM respectively) 
and the α-diketone is present is some clinical HCV protease inhibitors.  
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2.7 Combined optimization 
Based on the in vitro HNE and CtHtrA relative inhibition results above, where isoleucine and 
tertiary leucine were identified as optimal residues at P1 and P3 respectively, compounds retaining 
the diphenyl phosphonate combining P3 and P1 optimisation 8g, 8h along with an α-
ketoheterocycle transition state analogue 14d were synthesized. Compound 8h produced 
approximately 102.5 reduction in IFU counts at 100 µM (C. trachomatis) and a 103 reduction in 
IFU counts against C. pecorum at 100 µM (Figure 3).  
The benzothiazole analogue 14d failed to show in vitro CtHtrA inhibition with only moderate 
HNE inhibition, but showed some cellular activity against C. trachomatis (Figure 2), and a slightly 
improved activity at C. pecorum (103 reduction in IFU 100 µM; Figure 3). However, in contrast 
to the phosphonate compounds 8g and 8h which exhibited high chymotrypsin inhibition with IC50 
values of 1.28 ± 0.06 µM and 0.53 ± 0.04 µM respectively (Table 2); 14d showed no chymotrypsin 
inhibition (IC50> 500 µM) despite differing only at the transition state analogue (Table 3).  
As a measure of off-target effect, no inhibition of trypsin and chymotrypsin (IC50 > 500 µM) was 
observed for most of the active compounds except 8d, 8g and 8h which have isoleucine at P1 and 
the latter compound showing appreciable activity such to exclude it from further study . Compound 
8g showed higher potency compared to 8h against HNE (IC50 = 0.84 ± 0.05 µM; IC50 = 2.35 ± 
0.22µM) but only at a similar level to JO146. 
The dicarbonyl-containing compounds 18a-c and 30 (α-diketone and α-ketoamide respectively) 
exhibited an unexpected lack of biological activity. Both molecules lacked in vitro CtHtrA 
inhibition. This was extended to negligible cellular performance of the peptidyl α-ketoamide 30 
against C. trachomatis.  
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Unusual activity was observed for the boronic acid inhibitor 29. The compound activated CtHtrA 
at doses less than 50 µM, but displayed enzyme inhibition at higher doses (Figure S1). At 100 µM, 
it produced a 3 log reduction in IFU count against C. trachomatis (data not shown). Whilst the 
precise mechanism for the initial CtHtrA activation is unclear, the presence of the boronic acid 
moiety mimics a carboxylate terminus of a peptide substrate, which would bind to the PDZ1 
domain of CtHtrA and thus activating it towards proteolysis.17  
Generally, the noncovalent binders (peptidyl N-methylamides 24a-d, and the peptidyl valinol 28) 
lacked both biochemical (IC50 > 500µM) and cellular activity, indicating a covalent interaction 
between the inhibitor and the active site of CtHtrA is crucial for optimal activity. 
 
3. Conclusion 
We have found that inhibitors are required to interact with CtHtrA via a covalent interaction, either 
through reversible or irreversible transition state analogues. This is evident in both in vitro and in 
vivo data. The most potent compound identified was 8a (CtHtrA relative inhibition) which has 
retained the diphenylphosphonate moiety with the related compound 8d showing the highest 
activity against HNE. The identification of the α-ketobenzothiazole moiety as a selective reversible 
transition state analogue with in vitro activity against both human and koala pathogenic Chlamydia 
species, opens up another possible avenue to obtain more “drug-like” inhibitors of CtHtrA. This 
moves away from the previously identified irreversible diphenylphosphonate inhibitors. It also 
indicates that P1' optimization via the use of α-ketoheterocycles is a potential strategy for improved 
potency and selectivity.  
Optimization of binding affinity at CtHtrA subpockets via modification to inhibitor residues P1 
and P3 produced considerable improvement in potency and/or selectivity. Selectivity was obtained 
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over, trypsin and chymotrypsin and likely HNE, in addition to retaining cellular activity 
comparable with JO146 (1), when tertiary leucine was tested as the P3 residue (8a). This is also a 
viable means to obtain molecules with favourable pharmacokinetic properties, given that tertiary 
leucine is a non-natural amino acid, and may avoid recognition by degradative enzymes, thus 
potentially enhancing inhibitor performance in vivo. After testing numerous derivatives, valine 
remains the best residue at P1 for in vivo activity. Outside of selectivity, there seems no explanation 
as to why the α-diketoamide transition state analogues and the related α-diketone derivatives 
lacked activity given the use of the former in clinical protease inhibitors. It may be related to the 
more polar character as compared to the diphenyl phosphonates.  
CtHtrA is a complicated enzyme, which makes simple comparisons difficult. The enzyme is 
known to exist in at least 3 oligomeric states, an inactive hexamer and, following activation of the 
PDZ domain by a peptide terminal carboxylate, active 12-mers and 24-mers.16-17, 34  In addition, 
the covalent nature of the inhibitors complicates the use of explicit IC50 values hence the use of 
relative values.35 The allosteric activation of multiple monomers in a hexamer to then 
accommodate inhibitor binding adds further complexity. This is illustrated with the behaviour of 
the boronic acid derivative (29) which acted as both an activator and inhibitor (Figure S1). 
JO146 remains the most active inhibitor in terms of cellular performance, however potent 
analogues with malleable structural features and promising pharmacokinetic prospects have been 
identified. Further optimisation at P2 (proline) and P4 (Boc) to increase potency and reduce peptidic 
character is the next obvious step in moving towards clinically relevant protease inhibitors for the 





4.1. Compound Synthesis 
4.1.1. General Methods. All solvents and reagents were commercially procured (Sigma-Aldrich, 
Merck, AK Scientific, Thermo Scientific, Acros Organics, BDH, and Cambridge Isotope) and used 
without further purification. All reactions were conducted in standard glassware and in air or under 
nitrogen gas unless otherwise stated. Organic solvent extracts were dried with MgSO4 and 
subjected to rotary evaporation, and finally dried at 10-1 mbar using a high vacuum pump. 
Silica gel 60 (0.040-0.063 mm, 200-400 mesh) was used for flash column chromatography with 
all solvent systems expressed as volume to volume (v/v) ratios. Solids were recrystallized from a 
minimum amount of hot solvent and collected by vacuum filtration. Analytical thin layer 
chromatography (TLC) was performed on Merck TLC aluminium plates coated with 0.2 mm silica 
gel 60 F254. Spots were generally detected by UV (254 nm) and/or permanganate staining 
1H and 13C NMR spectra were recorded at room temperature on Varian 400 or 500 MHz 
spectrometers. Samples were prepared in deuterated solvents, chloroform (δ 7.26, 77.16 ppm) or 
acetonitrile (δ 1.95, 118.69 and 1.72 ppm) with the respective 1H and 13C chemical shifts shown 
in brackets. Chemical shifts (δ) are expressed in parts per million (ppm) and coupling constants 
(J) in Hertz (Hz), both measured against the residual solvent peak or internal standard 
tetramethylsilane (TMS). High resolution mass spectrometry were recorded on a Bruker 
microTOF-Q spectrometer with an electrospray ionization (ESI) source.  
The purity of compounds was determined by reverse-phase high performance liquid 
chromatography (HPLC) carried out on an Agilent HPLC with a Gemini 5 µm C18 110 Å column 
(250 × 4.6 mm, Phenomenex, New Zealand). Compounds were eluted using solvent A: 0.1% 
trifluoroacetic acid (TFA) in water and solvent B: 0.1% TFA in acetonitrile (ACN) over a linear 
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gradient (40% ACN to 85% ACN over 45 min). Compounds were detected at 254/210 nm with a 
flow rate of 1.0 mL/min. The purity of compound 28 was determined on a Shimadzu HPLC with 
a Gemini 5 µm C18 110 Å column (250 × 4.6 mm, Phenomenex, New Zealand). The compound 
was eluted using solvent A: 0.1% formic acid in water and solvent B: 0.1% formic acid in ACN in 
a linear gradient from 30 to 60% ACN over 60 min. The flow rate was 1.2 mL/min and compounds 
were detected at the wavelength of 224 nm.  Final compounds including those obtained as isomeric 
mixtures, are >95% pure unless otherwise stated, see supporting information for HPLC traces of 
the compounds. 
 
4.1.2. General Procedure for Synthesis of peptidyl phosphonates (1, 8a-h)20 
Compounds 7a-d (1 equiv.) were dissolved in 3 mL DMF. To this O-(Benzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluoro-phosphate (HBTU) (1.2 equiv.) and N,N-
Diisopropylethylamine (DIEA) (2.5 equiv.) were added to generate the activated esters. After 10 
min, compounds 6a-d (1.5 equiv.) were added and the reaction mixtures were stirred under 
nitrogen overnight. The mixtures were diluted with EtOAc (25 mL) and an equal amount of sodium 
bicarbonate (NaHCO3), washed with brine (6 × 25 mL), dried (MgSO4) and concentrated in vacuo. 
The crude products were purified by column chromatography (100% EtOAc). This yielded 1, 8a-
h, as diastereomeric mixtures with characteristic 13C-31P coupling. We have previously reported 
the full NMR and mass spectrometric characterization of JO146 1, as part of the stereochemical 
investigation of its two diastereomers.36 The analogues 8a-h are characterized as follows with 13C-







Using general procedure above, 0.17 g (0.52 mmol) 
of 7b was coupled to 0.30 g (0.78 mmol) of 6a to 
yield a brown oil, which formed a brown solid foam 
under reduced pressure (0.08 g, 25%). ~94% purity 
by HPLC; tr = 38.234 and 38.651 min. 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.24 (m, 5H), 7.20 – 
7.11 (m, 5H), 5.44 (d, J = 9.9 Hz, 0.5H), 5.25 (d, J = 9.9 Hz, 0.5H), 4.80 – 4.70 (m, 1H), 4.55 – 
4.48 (m, 1H), 4.35 – 4.26 (m, 1H), 3.83 – 3.51 (m, 2H), 2.48 – 2.33 (m, 2H), 2.10 – 1.81 (m, 3H), 
1.44 – 1.40 (m, 9H), 1.15 – 1.04 (m, 6H), 1.00 – 0.91 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 
172.9, 171.9, 171.7 (d, JC-P = 14.0 Hz), 171.4 (d, JC-P = 5.8 Hz), 155.72, 155.65, 150.4 (d, JC-P = 
10.0 Hz), 150.2, 150.1, 150.0, 130.9, 129.8 (d, JC-P = 1.0 Hz), 129.71 (d, JC-P = 1.0 Hz), 129.65 (d, 
JC-P = 0.9 Hz), 129.60 (d, JC-P = 0.9 Hz), 125.24, 125.14 (d, JC-P = 1.1 Hz), 125.07 (d, JC-P = 0.8 
Hz), 120.8 (d, JC-P = 4.0 Hz), 120.64 (d, JC-P = 4.4Hz), 120.63 (d, JC-P = 4.0 Hz), 120.4 (d, JC-P = 
4.3 Hz), 79.7, 79.5, 60.4, 60.1, 58.3, 51.2 (d, JC-P = 154.8 Hz),  51.0 (d, JC-P = 155.6 Hz), 48.61, 
48.58, 35.7, 35.5, 35.2, 29.7, 29.33 (d, JC-P = 3.9 Hz), 29.25 (d, JC-P = 3.9 Hz), 28.37, 28.35, 28.3, 
27.9, 27.6, 26.4, 26.3, 26.2, 25.4, 25.0, 20.57 (d, JC-P = 13.9 Hz), 20.28 (d, JC-P = 13.8 Hz), 18.0 
(d, JC-P = 4.7 Hz), 17.9 (d, JC-P = 4.4 Hz). ESI-MS (m/z): calcd for C32H46N3NaO7P (M + Na) m/z 








Using general procedure above, 0.08 g (0.25 mmol) 
of 7c was coupled to 0.15 g (0.38 mmol) of 6a to 
yield a brown oil which formed a brown solid foam 
under reduced pressure (0.10 g, 67%). HPLC tr = 
33.679 and 34.581 min. 1H NMR (400 MHz, CDCl3)  δ 7.56 – 7.44 (m, 1H), 7.34 – 7.09 (m, 10H), 
5.27 (d, J = 9.3 Hz, 0.5H), 5.12 (d, J = 9.0 Hz, 0.5H), 4.78 – 4.65 (m, 2H), 4.56 – 4.32 (m, 1H), 
3.74 – 3.52 (m, 2H), 3.45 – 3.36 (m, 1H), 2.47 – 2.27 (m, 2H), 2.20 – 2.08 (m, 1H), 2.02 – 1.75 
(m, 3H), 1.64 – 1.50 (m, 2H), 1.46 – 1.39 (m, 9H), 1.13 – 0.97 (m, 6H), 0.93 – 0.65 (m, 3H). 13C 
NMR (101 MHz, CDCl3) δ 173.9, 173.1, 171.0, 170.9 (d, JC-P = 7.1 Hz), 155.6, 155.5, 150.42 (d, 
JC-P = 9.1 Hz), 150.3, 150.2, 150.0 (d, JC-P = 9.1 Hz), 129.83 (d, JC-P = 1.1 Hz), 129.76 (d, JC-P = 
1.1 Hz), 129.73 (d, JC-P = 1.1 Hz), 129.67 (d, JC-P = 0.8 Hz), 129.63, 125.32 (d, JC-P = 2.0 Hz), 
125.26 (d, JC-P = 1.3 Hz), 125.10, 120.73 (d, JC-P = 4.1 Hz),  120.72 (d, JC-P = 4.1 Hz), 120.4 (d, 
JC-P = 4.4 Hz),  79.66, 59.90, 59.69, 51.1 (d, JC-P = 154.6 Hz),  50.9 (d, JC-P = 130.6 Hz),  47.4, 
47.3, 35.6, 35.1, 29.2 (d, JC-P = 4.1 Hz), 28.34, 28.33, 26.83, 26.81, 25.2, 25.0, 20.5 (d, JC-P = 13.8 
Hz), 20.3 (d, JC-P = 14.1 Hz), 18.77, 18.75, 17.9 (d, JC-P = 4.6 Hz), 17.8 (d, JC-P = 4.3 Hz), 13.7, 




Using general procedure above, 0.25 g (0.76 mmol) 
of 7d was coupled to 0.35 g (1.1 mmol) of 6a to 
yield a brown oil which formed a brown solid foam 
under reduced pressure (0.23 g, 49%). HPLC tr = 
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37.496 and 37.939 min. 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 10.4 Hz, 0.5H), 7.27 – 7.17 
(m, 5H), 7.17 – 7.08 (m, 5.5H), 5.27 (d, J = 9.5 Hz, 0.5H), 5.11 (d, J = 9.5 Hz, 0.5H), 4.84 – 4.64 
(m, 2H), 4.51 – 4.43 (m, 1H), 4.31 – 4.13 (m, 1H), 3.78 – 3.50 (m, 2H), 2.42 – 2.04 (m, 2H), 2.00 
– 1.63 (m, 3H), 1.60 – 1.47 (m, 2H), 1.43 – 1.32 (m, 9H), 1.11 – 0.97 (m, 6H), 0.92 (m, 2H), 0.85 
– 0.76 (m, 3H), 0.71 – 0.65 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 172.6, 171.3, 171.2, 155.7, 
155.6, 150.4, 150.3, 150.2, 150.1 (d, JC-P = 9.0 Hz), 150.0, 129.7, 129.62, 129.57, 125.25 (d, JC-P 
= 1.0 Hz), 125.20 (d, JC-P = 1.2 Hz), 125.07 (d, JC-P = 0.8 Hz), 125.04 (d, JC-P = 1.1 Hz), 120.7 (d, 
JC-P = 4.1 Hz), 120.6 (d, JC-P = 4.0 Hz), 120.42, 120.37, 120.3, 79.6, 79.5, 60.3, 60.0, 56.2, 56.1, 
51.3 (d, JC-P = 154.6 Hz), 51.0 (d, JC-P = 154.6 Hz), 48.0, 47.8, 37.83, 37.75, 29.3 (d, JC-P = 3.6 
Hz), 29.2 (d, JC-P = 3.8 Hz), 28.30, 28.29, 27.4, 25.2, 25.0, 24.3, 24.0, 20.5 (d, JC-P = 13.3 Hz), 
20.2 (d, JC-P = 13.7 Hz), 18.0 (d, JC-P = 5.1 Hz), 17.9 (d, JC-P = 4.6 Hz), 15.6, 15.2, 11.1, 10.9. ESI-
MS (m/z): calcd for C32H46N3NaO7P (M + Na) m/z 638.2971 found 638.2911. 
Tert-butyl-N-[(2S)-1-[(2S)-2-{[1-(diphenoxyphosphoryl)-2-
methylbutyl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (8d) 
Using general procedure above, 0.10 g (0.32 mmol) 
of 7a was coupled to 0.15 g (0.48 mmol) of 6d to 
yield a brown oil which formed a brown solid foam 
under reduced pressure (0.06 g, 31%). HPLC tr = 
37.845, 38.674 and 39.275 min. 1H NMR (400 MHz, Chloroform-d) δ 7.46 – 7.35 (m, 1H), 7.32 – 
7.10 (m, 10H), 5.36 (d, J = 9.6 Hz, 0.5H), 5.20 (d, J = 9.4 Hz, 0.5H), 4.96 – 4.68 (m, 2H), 4.52 – 
4.44 (m, 1H), 4.32 – 4.21 (m, 1H), 3.79 – 3.41 (m, 2H), 2.47 – 2.37 (m, 0.5H), 2.20 – 2.03 (m, 
2.5H), 2.02 – 1.74 (m, 4H), 1.49 – 1.36 (m, 9H), 1.16 – 1.02 (m, 3H), 0.99 – 0.78 (m, 9H). 13C 
NMR (101 MHz, CDCl3) δ 173.43, 173.37, 172.44, 172.39, 171.3 (d, JC-P = 6.5 Hz), 171.22 (d, 
JC-P = 6.5 Hz), 171.19 (d, JC-P = 5.7 Hz), 171.11, 171.06, 155.83, 155.80, 150.49, 150.47, 150.39, 
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150.37, 150.27, 150.17, 150.09, 150.07, 150.00, 129.73, 129.67, 129.57 (d, JC-P = 0.8Hz), 129.55 
(d, JC-P = 0.8 Hz), 125.30 (d, JC-P = 1.3 Hz), 125.27 (d, JC-P = 1.5 Hz), 125.10, 125.09, 125.07, 
120.74, 120.70, 120.67, 120.65, 120.64, 120.60, 120.47 (d, JC-P = 1.2 Hz), 120.42 (d, JC-P = 1.2 
Hz), 120.38 (d, JC-P = 4.3Hz), 120.36 (d, JC-P = 4.3 Hz), 79.67, 79.59, 60.27, 60.25, 59.9, 56.8, 
51.11 (d, JC-P = 154.1 Hz), 51.08 (d, JC-P = 155.1 Hz), 49.93, 49.90, 48.39, 48.35, 47.70, 47.68, 
36.2 (d, JC-P = 4.0 Hz), 35.5 (d, JC-P = 3.8 Hz), 31.4, 31.2, 29.7, 28.34, 28.31, 28.22, 27.60, 27.48, 
27.40, 27.34, 27.31, 27.25, 27.16, 26.98, 26.82, 25.24, 25.23, 24.95, 24.80, 24.75, 24.70, 19.6, 
19.5, 17.4, 17.30, 17.28, 16.5 (d, JC-P = 12.2 Hz), 16.1 (d, JC-P = 11.8 Hz), 15.14 (d, JC-P = 3.0 Hz), 
15.06 (d, JC-P = 2.8 Hz), 11.72, 11.71, 11.6, 11.4. ESI-MS (m/z): calcd for C32H46N3NaO7P (M + 
Na) m/z 638.2971 found 638.2940. 
Tert-butyl-N-[(2S)-1-[(2S)-2-{[1-(diphenoxyphosphoryl)butyl]carbamoyl}pyrrolidin-1-yl]-3-
methyl-1-oxobutan-2-yl]carbamate (8e) 
 Using general procedure above, 0.13 g (0.41 
mmol) of 7a was coupled to 0.19 g (0.62 mmol) of 
6c to yield a colorless oil which formed a white 
solid foam under reduced pressure (0.12 g, 48%). 
HPLC tr = 33.974 and 34.523 min. 
1H NMR (400 MHz, CDCl3)  δ 7.84 – 7.79 (m, 1H), 7.43 – 
7.04 (m, 10H), 5.28 (d, J = 9.6 Hz, 0.5H), 5.20 (d, J = 9.3 Hz, 0.5H), 4.85 – 4.70 (m, 1H), 4.53 – 
4.44 (m, 1H), 4.25 (dd, J = 9.3, 6.1 Hz, 1H), 3.76 – 3.47 (m, 2H), 2.42 – 2.31 (m, 0.5H), 2.25 – 
1.61 (m, 4.5H), 1.62 – 1.49 (m, 2H), 1.48 – 1.37 (m, 9H), 1.33 – 1.16 (m, 2H), 0.94 – 0.79 (m, 
9H). 13C NMR (101 MHz, CDCl3) δ 173.2, 171.03, 170.97, 155.8, 150.4, 150.3, 150.0 (d, JC-P = 
9.3 Hz) 130.9, 129.8, 129.74, 129.65 (d, JC-P = 0.8 Hz), 126.7, 125.3 (d, JC-P = 1.4 Hz) 125.19 (d, 
JC-P = 1.3 Hz), 120.62 (d, JC-P = 4.0 Hz), 120.40 (d, JC-P = 4.4 Hz), 115.4, 114.7, 113.5, 79.7, 60.3, 
60.0, 56.9, 56.8, 47.72, 46.71, 45.1, 31.89, 31.86, 31.4, 31.3, 29.7, 29.4, 28.34, 28.32, 27.5, 27.2, 
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25.2, 25.0, 22.7, 19.5, 19.4, 19.1, 19.0, 17.3, 14.1, 13.53 (d, JC-P = 1.0 Hz), 13.45. ESI-MS (m/z): 
calcd for C31H44N3NaO7P (M + Na) m/z 624.2815 found 624.2843. 
Tert-butyl-N-[(2S)-1-[(2S)-2-{[1-(diphenoxyphosphoryl)-2,2-
dimethylpropyl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (8f) 
Using general procedure above, 0.10 g (0.32 mmol) 
of 7a was coupled to 0.15 g (0.48 mmol) of 6b to 
yield a colorless oil which formed a white solid 
foam under reduced pressure (0.15 g, 77%). HPLC 
tr = 37.308 and 38.316 min. 
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.49 (m, 0.5H), 7.36 – 7.32 (m, 
0.5H), 7.32 – 7.20 (m, 5H), 7.20 – 7.09 (m, 5H), 5.33 (d, J = 9.3 Hz, 0.5H), 5.22 (d, J = 9.5 Hz, 
0.5H), 4.80 – 4.74 (m, 1H), 4.68 – 4.58 (m, 1H), 4.48 – 4.43 (m, 1H), 4.32 – 4.21 (m, 1H), 3.72 – 
3.48 (m, 2H), 2.19 – 1.92 (m, 4H), 1.85 – 1.75 (m, 1H), 1.46 – 1.36 (m, 9H), 1.24 – 1.09 (m, 9H), 
0.98 – 0.90 (m, 3H), 0.88 – 0.78 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 173.4, 172.6, 171.0 (d, 
JC-P = 5.9 Hz), 155.82, 155.76, 150.6 (d, JC-P = 10.2 Hz), 150.3 (d, JC-P = 10.2 Hz), 150.2, 150.07, 
150.0, 129.7, 129.6, 125.2 (d, JC-P = 1.3 Hz). 125.1 (d, JC-P = 1.2 Hz), 125.0 (d, JC-P = 2.8 Hz), 
120.8 (d, JC-P = 4.0 Hz), 120.7 (d, JC-P = 4.1 Hz), 120.34 (d, JC-P = 4.5 Hz), 120.27 (d, JC-P = 4.5 
Hz), 115.4, 114.5, 113.5, 79.63, 79.58, 60.4, 60.0, 56.8, 56.7, 55.7 (d, JC-P = 150.8 Hz), 55.0 (d, 
JC-P = 151.6 Hz), 47.8, 47.7, 35.2 (d, JC-P = 4.9 Hz), 34.9 (d, JC-P = 5.2 Hz), 31.31, 31.26, 30.3, 
28.3, 28.3, 27.60, 27.55, 27.48, 27.45, 27.39, 25.2, 24.9, 19.7, 19.6, 17.3. ESI-MS (m/z): calcd for 








 Using general procedure above, 0.14 g (0.44 
mmol) of 7d was coupled to 0.21 g (0.66 mmol) of 
6d to yield a colorless oil  which formed a brown 
solid foam under reduced pressure (0.10 g, 37%). 
HPLC tr = 41.076, 41.471 and 42.094 min).
 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.40 (m, 0.5H), 
7.36 (d, J = 10.0 Hz, 0.5H), 7.30 – 7.22 (m, 4H), 7.20 – 7.06 (m, 6H), 5.30 – 5.24 (m, 0.5H), 5.11 
(d, J = 9.5 Hz, 0.5H), 4.94 – 4.68 (m, 2H), 4.48 – 4.42 (m, 1H), 4.30 – 4.15 (m, 1H), 3.75 – 3.49 
(m, 2H), 2.16 – 2.06 (m, 2H), 1.97 – 1.64 (m, 3H), 1.59 – 1.47 (m, 2H), 1.43 – 1.34 (m, 9H), 1.28 
– 1.19 (m, 2H), 1.11 – 1.01 (m, 4H), 0.91 – 0.66 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 173.6, 
172.61, 172.55, 171.3 (d, JC-P = 6.4 Hz), 171.1 (d, JC-P = 6.3 Hz), 170.0 (d, JC-P = 6.3 Hz), 155.7, 
155.6, 150.4 (d, JC-P = 9.7 Hz), 150.3, 150.2, 150.10, 150.07, 150.0, 129.8, 129.7, 129.63, 129.56, 
125.4, 125.3, 125.2 (d, JC-P = 1.2 Hz), 125.0, 120.72 (d, JC-P = 3.8 Hz), 120.65 (d, JC-P = 3.9 Hz), 
120.60, 120.56, 120.4 (d, JC-P = 3.0 Hz), 115.4, 79.7, 79.6, 60.3, 59.9, 56.24, 56.15, 52.1, 51.8, 
51.73, 51.65, 50.3, 50.2, 50.1, 49.9, 49.8, 48.3, 48.2, 47.9, 47.8, 37.9, 37.8, 37.7, 36.2, 36.14, 
36.10, 35.6 (d, JC-P = 3.6 Hz), 35.5 (d, JC-P = 3.7 Hz), 35.40 (d, JC-P = 4.1 Hz), 28.31, 28.29, 27.5, 
27.4, 27.2, 27.1, 26.99, 26.96, 26.8, 25.21, 25.20, 24.9, 24.81, 24.76, 24.7, 24.30, 24.28, 24.1, 24.0, 
23.0, 16.4 (d, JC-P = 12.0 Hz), 16.3 (d, JC-P = 11.7 Hz), 16.1 (d, JC-P = 11.8 Hz), 15.50, 15.47, 15.3, 
15.1 (d, JC-P = 2.9 Hz), 15.0, 11.74, 11.73, 11.70, 11.69, 11.53, 11.51, 11.4, 11.1, 10.9. ESI-MS 







 Using general procedure above, 0.50 g (1.50 
mmol) of 7b was coupled to 0.73 g (2.25 mmol) of 
6d to yield a colorless oil which formed a brown 
solid foam under reduced pressure (0.35 g, 37%). 
HPLC tr = 41.897, 42.294 and 42.817 min.
 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 10.4 Hz, 
0.5H), 7.28 – 7.18 (m, 5H), 7.16 – 7.09 (m, 5.5H), 5.44 (d, J = 9.9 Hz, 1H), 4.96 – 4.70 (m, 2H), 
4.49 (dd, J = 8.1, 3.7 Hz, 1H), 4.32 – 4.24 (m, 1H), 3.77 – 3.58 (m, 2H), 2.11 – 1.98 (m, 2H), 1.95 
– 1.74 (m, 3H), 1.48 – 1.34 (m, 9H), 1.32 – 1.19 (m, 2H), 1.11 – 1.04 (m, 3H), 0.99 – 0.92 (m, 
6H), 0.92 – 0.80 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 171.8, 171.7, 171.5, 155.7, 155.6, 150.4 
(d, JC-P = 9.7 Hz), 150.1 (d, JC-P = 9.3 Hz), 129.79 (d, JC-P = 1.0 Hz), 129.71, 129.58 (d, JC-P = 0.9 
Hz), 129.55 (d, JC-P = 0.8 Hz), 129. 3, 125.23, 125.19, 125.09, 125.0, 120.76 (d, JC-P = 4.0 Hz), 
120.74, 120.65, 120.61, 120.57, 120.47, 120.4, 120.3, 115.4, 79.6, 79.5 (d, JC-P = 1.7 Hz), 60.3, 
60.0, 58.3, 51.1 (d, JC-P = 154.5 Hz), 51.0 (d, JC-P = 154.8 Hz), 49.9, 48.6, 48.3, 36.0, 35.7, 35.64, 
35.56, 28.4, 28.3, 28.0, 27.8, 26.9, 26.8, 26.21, 26.16, 25.3 (d, JC-P = 2.1 Hz), 25.0, 24.7 (d, JC-P = 
5.2 Hz), 16.5 (d, JC-P = 12.0 Hz), 16.1 (d, JC-P = 11.8 Hz), 15.2, 14.3, 11.9, 11.71, 11.70, 11.6, 
11.3. ESI-MS (m/z): calcd for C33H48N3NaO7P (M + Na) m/z 652.3128 found 652.3071. 
4.1.3. General Procedure for Synthesis of peptidyl α-ketoheterocycles (14a-e).  
To a solution of heterocycle (1 equiv.) in 2 mL dry THF was added n-butyllithium (2.18 M, 8.3 
equiv.) slowly over 3 min at -78 ℃, and the mixture was stirred for an additional 10 min. A solution 
of 13a-e (3.3 equiv. ) in 1.5 mL dry THF was added rapidly over 1 minute and the mixture stirred 
for 15 minutes at -78 ℃. The reaction mixture was poured into saturated NH4Cl and extracted with 
EtOAc. The combined organic extracts were washed with saturated NaHCO3, dried (MgSO4) and 
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concentrated in vacuo. The crude product was purified by column chromatography eluting with 
EtOAc: Hexane (1:2) to obtain compounds 14a-e as mixtures of diastereomers.  
Tert-butyl-N-[(2S)-3-methyl-1-[(2S)-2-{[(2S)-3-methyl-1-oxo-1-(1,3-thiazol-2-yl)butan-2-
yl]carbamoyl}pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate (14a) 
Using the general method described for Peptidyl α-
ketoheterocycles, 0.18 g (0.40 mmol) of 13a was reacted 
with lithiated thiazole to yield a brown oil which formed 
a light brown foam under reduced pressure. Recovered as a mixture of diastereomers (0.036 g, 
54%). HPLC tr = 22.702 and 23.587 min. 
1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 3.0 Hz, 1H), 
7.67 (dd, J = 4.5, 3.0 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 5.58 (dd, J = 8.2, 4.9 Hz, 1H), 5.30 (d, J = 
9.3 Hz, 1H), 4.63 (dd, J = 8.1, 2.9 Hz, 1H), 4.28 (dd, J = 9.4, 6.1 Hz, 1H), 3.75 – 3.57 (m, 2H), 
2.43 – 2.25 (m, 2H), 2.14 – 1.87 (m, 4H), 1.41 (s, 9H), 1.04 – 0.94 (m, 6H), 0.93 (d, J = 6.8 Hz, 
3H), 0.85 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 191.6, 172.5, 171.0, 170.9, 165.4, 
155.8, 145.0, 144.9, 126.6, 126.5, 79.5, 59.93, 59.91, 56.8, 47.7, 31.5, 31.0, 30.9, 28.3, 27.3, 26.9, 
25.1, 25.0, 20.1, 19.9, 19.6, 19.6, 17.4, 17.3, 17.2, 17.0. ESI-MS (m/z): calcd for C23H36N4NaO5S 
(M + Na) m/z 503.2304 found 503.2272. 
Tert-butyl-N-[(2S)-3-methyl-1-oxo-1-[(2S)-2-{[(2S)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-
yl]carbamoyl}pyrrolidin-1-yl]butan-2-yl]carbamate (14b) 
Using the general method described for Peptidyl α-
ketoheterocycles, 0.18 g (0.40 mmol) of 13b was reacted 
with lithiated thiazole to yield a brown oil which formed 
a brown foam under reduced pressure (0.03 g, 45%). HPLC tr = 24.086 and 24.852 min.
1H NMR 
(400 MHz, CDCl3) δ 8.06 – 7.95 (m, 1H), 7.71 – 7.63 (m, 1H), 7.57 (d, J = 7.8 Hz, 0.5H), 7.45 (d, 
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J = 7.5 Hz, 0.5H), 5.67 – 5.56 (m, 1H), 5.31 – 5.22 (m, 1H), 4.74 – 4.58 (m, 1H), 4.35 – 4.22 (m, 
1H), 3.75 – 3.56 (m, 2H), 2.44 – 2.25 (m, 2H), 2.12 – 1.85 (m, 5H), 1.71 – 1.49 (m, 2H), 1.45 – 
1.37 (m, 9H), 1.03 – 0.86 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 208.9, 208.7, 191.7, 191.4, 
172.9, 172.4, 170.8, 170.6, 164.79, 164.77, 155.8, 145.02, 144.97, 126.6, 126.5, 79.5, 59.7, 56.80, 
56.77, 55.23, 55.20, 47.6, 47.5, 40.9, 39.5, 39.4, 38.6, 34.6, 33.4, 33.3, 31.4, 31.3, 28.3, 28.2, 27.5, 
27.4, 27.2, 27.0, 25.52, 25.51, 25.1, 24.9, 23.9, 23.9, 22.2, 20.9, 20.8, 19.6, 19.4, 18.84, 18.83, 
18.6, 18.5, 17.49, 17.47, 17.33, 17.19, 14.6, 13.84, 13.80, 13.79, 13.74, 13.72, 13.67. ESI-MS 
(m/z): calcd for C23H36N4NaO5S (M + Na) m/z 503.2304 found 503.2287. 
Tert-butyl-N-[(2S)-1-[(2S)-2-{[(2S)-1-(1,3-benzothiazol-2-yl)-3-methyl-1-oxobutan-2-
yl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (14c) 
Using the general method described for Peptidyl α-
ketoheterocycles, 0.23 g (0.50 mmol) of 13a was 
reacted with lithiated benzothiazole to yield a 
colourless oil which formed a white foam under reduced pressure (0.10 g, 50%). HPLC tr = 34.802 
and 35.474 min. 1H NMR (400 MHz, CDCl3) δ 8.22 – 8.15 (m, 1H), 7.99 – 7.93 (m, 1H), 7.72 (d, 
J = 8.3 Hz, 0.5H), 7.58 – 7.47 (m, 2.5H), 5.77 – 5.67 (m, 1H), 5.30 – 5.22 (m, 1H), 4.75 (dd, J = 
8.1, 2.3 Hz, 0.5H), 4.65 (dd, J = 8.1, 2.9 Hz, 0.5H), 4.34 – 4.27 (m, 1H), 3.75 – 3.57 (m, 2H), 2.54 
– 2.24 (m, 2H), 2.14 – 1.89 (m, 4H), 1.43 (s, 9H), 1.11 – 1.00 (m, 6H), 0.97 – 0.92 (m, 3H), 0.89 
(dd, J = 8.7, 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 193.3, 193.1, 173.2, 172.6, 171.0, 170.9, 
164.60, 164.55, 155.8, 153.6, 137.3, 137.2, 127.84, 127.81, 127.0, 125.79, 125.75, 122.31, 122.28, 
79.6, 60.0, 59.9, 59.7, 56.8, 47.7, 47.6, 31.5, 31.4, 31.1, 30.9, 28.3, 27.3, 26.8, 25.1, 25.0, 20.0, 
19.95, 19.7, 19.6, 17.5, 17.4, 17.3, 17.2. ESI-MS (m/z): calcd for C27H38N4NaO5S (M + Na) m/z 




yl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl] carbamate (14d) 
Using the general method described for Peptidyl α-
ketoheterocycles, 0.50 g (0.30 mmol) of 13d was 
reacted with lithiated benzothiazole to yield a dark 
brown oil which formed a dark brown foam under reduced pressure (0.15 g, 28%). HPLC tr = 
44.367 and 45.645 min. 1H NMR (400 MHz, CDCl3) δ 8.19 – 8.11 (m, 1H), 7.97 – 7.91 (m, 1H), 
7.78 (d, J = 8.3 Hz, 0.5H), 7.57 – 7.47 (m, 2.5H), 5.89 (dd, J = 8.3, 3.7 Hz, 0.5H), 5.74 (dd, J = 
8.2, 5.4 Hz, 0.5H), 5.30 (dd, J = 9.4, 5.9 Hz, 1H), 4.77 – 4.68 (m, 0.5H), 4.63 – 4.55 (m, 0.5H), 
4.34 – 4.27 (m, 1H), 3.78 – 3.59 (m, 2H), 2.31 – 2.06 (m, 2H), 1.98 – 1.81 (m, 3H), 1.43 – 1.37 
(m, 9H), 1.25 – 1.10 (m, 2H), 1.07 – 0.93 (m, 12H), 0.87 – 0.80 (m, 3H). 13C NMR (101 MHz, 
CDCl3) δ 193.6, 192.9, 172.9, 172.1, 171.01, 170.9, 164.8, 164.4, 155.7, 153.6, 153.5, 137.3, 
137.2, 127.8, 127.7, 127.0, 126.9, 125.8, 125.7, 122.3, 122.2, 79.6, 59.9, 59.6, 58.3, 48.6, 37.8, 
36.9, 35.6, 35.5, 28.3, 27.3, 26.3, 25.2, 25.1, 24.3, 16.2, 14.0, 11.9, 11.4. ESI-MS (m/z): calcd for 
C29H42N4NaO5S (M + Na) m/z 581.2774 found 581.2748. 
Tert-butyl-N-[(2S)-3-methyl-1-[(2S)-2-{[(2S)-3-methyl-1-(1-methyl-1H-imidazol-2-yl)-1-
oxobutan-2-yl]carbamoyl}pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate (14e) 
Using the general method described for Peptidyl α-
ketoheterocycles, 0.43 g (0.94 mmol) of 13a was 
reacted with lithiated N-methylimidazole to yield a 
yellow oil which formed a light yellow foam under reduced pressure (0.07 g, 54%). HPLC tr = 
11.818 and 13.022 min. 1H NMR (CD3CN, 400 MHz) δ 7.46 – 7.37 (m, 0.5H), 7.27 – 7.22 (m, 
1.5H), 7.15 – 7.11 (m, 1H), 5.49 – 5.45 (m, 0.5H), 5.34 (dd, J = 9.3, 6.0 Hz, 0.5H), 4.53 – 4.44 
(m, 1H), 4.25 – 4.18 (m, 1H), 3.95 – 3.90 (m, 3H), 3.74 – 3.61 (m, 2H), 2.33 – 2.25 (m, 1H), 2.08 
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– 1.88 (m, 6H), 1.44 – 1.38 (m, 9H), 1.00 – 0.96 (m, 3H), 0.94 – 0.87 (m, 6H), 0.84 (dd, J = 6.9, 
1.2 Hz, 3H).13C NMR (101 MHz, CD3CN) δ 191.5, 191.2, 173.2, 173.1, 172.9, 172.7, 157.1, 143.1, 
142.9, 130.2, 129.5, 80.0, 61.62, 61.59, 61.4, 60.6, 58.4, 48.8, 38.0, 37.0, 33.1, 32.7, 32.1, 30.1, 
29.6, 29.0, 26.2, 26.0, 20.7, 20.6, 20.3, 20.7, 18.3, 18.1. ESI-MS (m/z): calcd for C24H39N5O5 (M 
+ Na) m/z 500.2843; found 500.2815.  
4.1.4. General Procedure for synthesis of peptidyl α-diketones (18a-c).  
Wet DCM was prepared by solvating 2.6 µL (1.1 equiv.) of water in 2.6 mL of DCM, and this was 
slowly added to a stirring solution of 17a-c (1 equiv.) and DMP (2 equiv.) in 1.0 mL of dry DCM 
under nitrogen. The translucent solution grew cloudy towards the end of the reaction which took 
~20 min. The reaction mixture was diluted in diethyl ether and concentrated under vacuum. The 
residue was further dissolved in 5 mL diethyl ether and washed with 5 mL of 1:1 10% Na2S2O3: 
saturated NaHCO3 followed by 3 mL of water and 3 mL of brine. The aqueous fraction was 
extracted with diethyl ether (7 mL). The combined organic layers were washed with water and 
brine, and dried over MgSO4 and concentrated under vacuum.  The crude product was purified by 
column chromatography. Compounds 18a-c were eluted as a mixtures of diastereomers with 
EtOAc: Hexane (1:1). 
Tert-butyl-N-[(2S)-3-methyl-1-[(2S)-2-{[(3S)-2-methyl-4,5-dioxohexan-3-
yl]carbamoyl}pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate (18a) 
Using the general method described for Peptidyl α-
diketones, 0.24 g (0.54 mmol) of 17a was oxidized to yield 
a bright yellow solid which formed a yellow foam under 
reduced pressure (0.05 g, 21%). NMR and HPLC spectra revealed this to be a mixture of 
diastereomers. Purity not determined by HPLC. 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 6.8 Hz, 
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0.5H), 7.48 (d, J = 6.2 Hz, 0.5H), 5.26 – 5.15 (m, 1H), 4.90 – 4.80 (m, 1H), 4.68 – 4.54 (m, 1H), 
4.31 – 4.21 (m, 1H), 3.72 – 3.51 (m, 2H), 2.39 – 2.22 (m, 1H), 2.14 – 1.77 (m, 5H), 1.48 – 1.33 
(m, 9H), 1.12 – 0.71 (m, 15H). 13C NMR (101 MHz, CDCl3) δ 196.77, 196.75, 196.6, 196.5, 
173.20, 172.95, 171.03, 171.02, 155.8, 79.7, 59.4, 59.3, 58.3, 58.1, 56.83, 56.79, 47.7, 47.6, 31.4, 
31.3, 29.7, 29.6, 28.3, 26.6, 26.5, 25.1, 25.0, 23.85, 23.82, 19.7, 19.6, 19.53, 19.46, 17.9, 17.7, 
17.5, 17.3. ESI-MS (m/z): calcd for C22H37N3NaO6 (M+ Na) m/z 462.2580 found 462.2544. 
Tert-butyl-N-[(2S)-3-methyl-1-[(2S)-2-{[(3S)-2-methyl-4,5-dioxoheptan-3-
yl]carbamoyl}pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate (18b) 
Using the general method described for Peptidyl α-
diketones, 0.06 g (0.13 mmol) of 17b was oxidized to 
yield a yellow solid which formed a yellow foam under 
reduced pressure (0.04 g, 67%). Purity not determined by HPLC. 1H NMR (400 MHz, CDCl3) δ 
7.09 (d, J = 8.3 Hz, 1H), 5.25 (d, J = 9.2 Hz, 1H), 4.60 – 4.53 (m, 1H), 4.49 (dd, J = 8.3, 4.4 Hz, 
1H), 4.29 (dd, J = 9.3, 6.1 Hz, 1H), 3.75 – 3.59 (m, 2H), 2.30 – 2.25 (m, 1H), 2.21 – 1.87 (m, 7H), 
1.42 (s, 9H), 1.00 (dd, J = 7.0, 3.1 Hz, 3H), 0.96 – 0.85 (m, 9H), 0.80 (dd, J = 6.9, 3.0 Hz, 3H).13C 
NMR (101 MHz, CDCl3) δ 199.59, 199.55, 197.0, 196.9, 171.04, 171.00, 155.8, 79.6, 60.8, 59.4, 
59.3, 58.5, 58.3, 56.8, 47.7, 47.6, 36.1, 31.4, 31.3, 29.66, 29.65, 29.62, 29.59, 28.3, 28.2, 26.7, 
26.5, 25.1, 25.0, 19.8, 19.7, 19.6, 19.5, 18.69, 18.66, 17.8, 17.7, 17.5, 17.4, 17.3, 14.1, 6.80, 6.77. 
ESI-MS (m/z): calcd for C23H39N3NaO6 (M + Na) m/z 476.2737 found 476.2715. 
Tert-butyl-N-[(2S)-1-[(2S)-2-{[(3S)-1-cyclopropyl-4-methyl-1,2-dioxopentan-3-
yl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (18c) 
Using the general method described for Peptidyl α-
diketones, 0.18 g (0.38 mmol) of 17c was oxidized to 
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yield a yellow solid which formed a yellow foam under reduced pressure (0.035 g, 20%). <95% 
purity by HPLC; tr = 24.818 and 25.584. 
1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz, 
Chloroform-d) δ 7.59 (d, J = 7.4 Hz, 0.5H), 7.41 (d, J = 7.1 Hz, 0.5H), 5.27 – 5.20 (m, 1H), 5.04 
– 4.93 (m, 1H), 4.70 – 4.59 (m, 1H), 4.33 – 4.24 (m, 1H), 3.73 – 3.54 (m, 2H), 2.71 – 2.61 (m, 
1H), 2.40 – 2.28 (m, 1H), 2.14 – 1.81 (m, 5H), 1.46 – 1.36 (m, 9H), 1.16 – 1.04 (m, 4H), 1.03 – 
0.79 (m, 12H).13C NMR (101 MHz, CDCl3) δ 198.32, 198.27, 196.6, 196.5, 173.2, 172.8, 171.0, 
170.9, 155.8, 79.6, 59.6, 59.5, 58.4, 58.3, 56.8, 47.7, 47.6, 31.43, 31.37, 29.9, 29.72, 29.66, 28.3, 
28.2, 26.9, 26.6, 25.1, 25.0, 19.8, 19.7, 19.6, 19.5, 17.6, 17.47, 17.45, 17.35, 15.53, 15.50, 13.8, 
13.7, 13.49, 13.45. ESI-MS (m/z): calcd for C24H39N3NaO6 (M+ Na) m/z 488.2737 found 
488.2698. 
4.1.5. General Procedure for synthesis of peptidyl N-methylamides (24a-d).  
Compound 7a (1 equiv.) was dissolved in 7 mL DMF. To this was added HBTU (1.2 equiv.) and 
DIEA (2.5 equiv.) to generate the activated ester. After 10 minutes, 23a-d (1.5 equiv.) was added 
and the reaction mixture was stirred under nitrogen overnight. The reaction was diluted with 
EtOAc (50 mL) and an equal amount of NaHCO3, washed with brine (6 × 50 mL), dried (MgSO4) 
and concentrated under vacuum. The crude product was subjected to column chromatography 




Using the procedure described for the synthesis of Peptidyl 
N-methylamides, 0.25 g (0.81 mmol) of 7a was coupled to 
0.17 g (1.18 mmol) of 23a to yield a colourless oil which formed a white solid foam under reduced 
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pressure (0.35 g, 99%). HPLC tr =  12.232 min. 
1H NMR (400 MHz, CDCl3) δ 7.04 (d, J = 8.8 Hz, 
1H), 5.35 (d, J = 9.3 Hz, 1H), 4.73 (dd, J = 8.8, 6.3 Hz, 1H), 4.51 (dd, J = 8.0, 3.4 Hz, 1H), 4.27 
(dd, J = 9.4, 5.9 Hz, 1H), 3.74 – 3.57 (m, 2H), 3.06 (s, 3H), 2.93 (s, 3H), 2.15 – 2.06 (m, 2H), 2.02 
– 1.89 (m, 4H), 1.39 (s, 9H), 0.97 (d, J = 6.8 Hz, 3H), 0.93 – 0.81 (m, 9H). 13C NMR (101 MHz, 
CDCl3) δ 171.8, 171.5, 171.1, 155.9, 79.3, 60.1, 56.7, 53.6, 47.5, 37.3, 35.6, 31.7, 31.4, 28.3, 




Using the procedure described for the synthesis of 
Peptidyl N-methylamides, 0.25 g (0.81 mmol) of 7a was 
coupled to 0.19 g (1.21 mmol) of 23b to yield a colourless oil which formed a white solid foam 
under reduced pressure (0.24 g, 66%). HPLC tr = 15.392 min. 
1H NMR (400 MHz, CDCl3) δ 7.02 
(d, J = 8.9 Hz, 1H), 5.38 – 5.26 (m, 1H), 4.71 – 4.64 (m, 1H), 4.53 – 4.45 (m, 1H), 4.27 (dd, J = 
9.4, 5.8 Hz, 1H), 3.74 – 3.57 (m, 2H), 3.52 – 3.22 (m, 2H), 3.05 – 2.85 (2  s, 3H), 2.15 – 2.05 (m, 
2H), 2.00 – 1.89 (m, 4H), 1.39 (s, 9H), 1.18 – 1.05 (m, 3H), 0.97 (dd, J = 6.8, 0.9 Hz, 3H), 0.93 – 
0.83 (m, 9H).13C NMR (101 MHz, CDCl3) δ 171.82, 171.79, 171.2, 171.13, 171.08, 170.8, 155.9, 
79.3, 60.2, 56.7, 53.7, 53.6, 47.5, 44.4, 42.7, 34.8, 32.8, 32.0, 31.7, 31.4, 28.32, 28.27, 25.2, 25.1, 
19.64, 19.57, 19.5, 17.6, 17.5, 17.24, 17.21, 12.1. ESI-MS (m/z): calcd for C23H42N4NaO5 (M + 





Using the procedure described for the synthesis of 
Peptidyl N-methylamides, 0.25 g (0.81 mmol) of 7a 
was coupled to 0.21 g (1.21 mmol) of 23c to yield a 
light yellow oil which formed a light yellow foam under reduced pressure (0.32 g, 86%). HPLC  tr 
= 17.086 min.1H NMR (400 MHz, CDCl3) δ 6.97 (d, J = 9.2 Hz, 1H), 5.36 (d, J = 9.3 Hz, 1H), 
5.16 (dd, J = 9.2, 7.0 Hz, 1H), 4.50 (dd, J = 8.0, 3.6 Hz, 1H), 4.26 (dd, J = 9.4, 5.9 Hz, 1H), 3.73 
– 3.57 (m, 2H), 2.88 (s, 3H), 2.75 – 2.66 (m, 1H), 2.14 – 2.04 (m, 2H), 2.01 – 1.89 (m, 4H), 1.38 
(s, 9H), 0.95 (d, J = 6.8 Hz, 3H), 0.91 – 0.85 (m, 9H), 0.84 – 0.75 (m, 2H), 0.71 – 0.54 (m, 2H). 
13C NMR (101 MHz, CDCl3)
   δ 174.4, 171.8, 171.1, 155.9, 79.3, 60.1, 56.7, 54.7, 47.5, 34.3, 31.9, 
31.4, 31.1, 28.3, 28.2, 25.1, 19.6, 19.6, 17.8, 17.2, 10.2, 8.0. ESI-MS (m/z): calcd for 
C24H42N4NaO5 (M + Na) m/z 489.3053 found 489.3008. 
Tert-butyl-N-[(2S)-3-methyl-1-[(2S)-2-{[(1S)-2-methyl-1-[methyl(prop-2-en-1-
yl)carbamoyl]propyl]carbamoyl}pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate (24d) 
Using the procedure described for the synthesis of 
Peptidyl N-methylamides, 0.35 g (1.11 mmol) of 7a 
was coupled to 0.28 g (1.67 mmol) of 23a to yield a light yellow oil which formed a light yellow 
solid foam under reduced pressure (0.46 g, 88%). HPLC tr = 17.612 min. 
1H NMR (400 MHz, 
CDCl3) δ 7.12 – 7.05 (m, 1H), 5.78 – 5.61 (m, 1H), 5.44 – 5.35 (m, 1H), 5.18 – 5.05 (m, 2H), 4.75 
– 4.61 (m, 1H), 4.56 – 4.47 (m, 1H), 4.26 (dd, J = 9.4, 6.0 Hz, 1H), 4.11 – 3.79 (m, 2H), 3.74 – 
3.56 (m, 2H), 3.01 – 2.85 (2  s, 3H), 2.16 – 2.05 (m, 2H), 2.00 – 1.87 (m, 4H), 1.39 (s, 9H), 0.96 
(dd, J = 6.8, 2.1 Hz, 3H), 0.92 – 0.81 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 171.9, 171.7, 171.24, 
171.22, 171.1, 155.9, 132.6, 132.5, 117.5, 117.4, 79.3, 60.12, 60.10, 56.7, 53.84, 53.76, 52.1, 50.2, 
47.6, 34.8, 33.5, 31.8, 31.6, 31.4, 28.31, 28.27, 25.1, 19.7, 19.5, 19.5, 17.6, 17.5, 17.30, 17.26. 
ESI-MS (m/z): calcd for C24H42N4NaO5 (M + Na) m/z 489.3053 found 489.3014. 
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4.1.6. Synthesis of peptidyl valinol (28).  
Tert‐butyl N‐[(2S)‐1‐[(2S)‐2‐{[(2S)‐1‐hydroxy‐3‐methylbutan‐2‐yl]carbamoyl}pyrrolidin‐1‐
yl]‐3‐methyl‐1‐oxobutan‐2‐yl]carbamate (28) 
Pre-synthesized Boc-Val-Pro-valinol benzyl ether 27 (0.19 
g, 0.38 mmol) was dissolved in a mixture of 
methanol/water/acetic acid 9:0.9:0.1 (5 ml). Palladium-
carbon 5% (0.11 g, 0.05 mmol) was added to this solution while stirring, then a balloon with 
hydrogen was attached and the flask was purged with hydrogen gas under vacuum. The mixture 
was stirred under hydrogen for 17 hr. TLC confirmed the completion of the reaction. The mixture 
was filtered over celite and the solvent was evaporated under reduced pressure. The crude product 
was purified by column chromatography (eluent: 100% chloroform) to give 28 (0.132 g, 86%). 
HPLC tr = 32.542 min 
1H. NMR (400 MHz, CDCl3) δ 7.01 (d, J = 7.1 Hz, 1H), 5.31 (d, J = 9.2 
Hz, 1H), 4.55 (dd, J = 8.1, 3.2 Hz, 1H), 4.26 (dd, J = 9.3, 6.3 Hz, 1H), 3.99 (dd, J = 8.4, 5.6 Hz, 
1H), 3.76 – 3.56 (m, 5H), 2.36  – 2.24 (m, 1H), 2.05 – 1.76 (m, 5H), 1.40 (d, J = 2.1 Hz, 9H), 1.00 
– 0.83 (m, 12H). 13C NMR (400 MHz, CDCl3) δ 172.8, 171.8, 171.7, 170.5, 157.0, 155.8, 80.8, 
79.6, 63.6, 62.4, 61.2, 60.3, 57.7, 57.59, 57.56, 57.0, 47.8, 46.6, 31.7, 31.3, 30.5, 29.0, 28.8, 28.33, 
28.31, 27.5, 25.2, 21.9, 19.7, 19.5, 19.4, 19.3, 18.8, 17.5, 17.4. ESI-MS (m/z): calcd for calculated 
for C20H37N3NaO5 (M + Na) m/z 422.2650 found 422.2625.  
4.2. Protein Expression and Purification. The expression and purification of recombinant 
CtHtrA was conducted according to our previously reported procedure.16  
4.3. Protease Assays.  
In vitro CtHtrA inhibition studies were conducted as previously reported.17 The assay was carried 
out in black 96-well plates at an excitation wavelength of 340 nm and emission wavelength of 405 
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nm on a POLARstar Optima (BMG Labtech) plate reader. Readings were obtained 50 cycles at 
the minimum cycle time of 10 flashes per well and a gain of 2000 with orbital shaking for 1 sec 
before each cycle. The activity of CtHtrA and its inhibition were measured by incubating the 
enzyme (14.4 µL; 0.5 mg/mL) with 5 µL of different concentrations of inhibitors (dissolved in 
DMSO) made up to a final volume of 150 µL in 50 mM Tris/20 mM MgCl2 (pH 7.0) buffer. 
Incubation was carried out at 37 ℃ for 20 min, this was followed by adding 10 µL of the custom-
synthesized fluorescent peptide MeOCoum-ENLHLPLPIIF-NH-DNP (Mimotopes) with 7-
methoxycoumarin-4-acetic acid (MCA) as fluorophore (MeOCoum) and 2,4-dinitrophenol (DNP) 
as quencher; made to a concentration of 1 mg/mL in 50% isopropanol, and fluorescence readings 
were acquired immediately.  
The inhibition of HNE, trypsin and chymotrypsin was conducted by modifying an existing 
method.37 The activity of the enzymes was measured at 37 °C over a period of 5 min using AAPV-
pNA (Sigma-Aldrich M4765), Nα-Benzoyl-DL-R-pNA (Sigma-Aldrich B4875) and Suc-AAPF-
pNA (Sigma-Aldrich S7388) as HNE, trypsin and chymotrypsin substrates respectively. 
Absorbance readings were measured at 405 nm and monitored at 15 sec intervals.  
Enzyme inhibition was assessed by incubating 50 µL of the appropriate enzyme solutions in the 
assay buffer (0.10 M Tris-HCl, pH 8.1, 0.02 M CaCl2) with 1.5 µL of the inhibitors dissolved in 
DMSO, and made up to 100 µL in the assay buffer. The mixture was incubated at 37 °C for 15 
min before the addition of 50 µL of the substrate which initiated the reaction to give an intense 
yellow coloration for controls and wells without enzyme inhibition.  
All experiments were conducted in triplicate and inhibition was measured as the percentage of 
enzyme activity remaining. Compounds were tested against CtHtrA in 3 separate batches, each 
time giving a different IC50 value for JO146 but with low errors across replicates (Table S3). The 
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trend of the results were consistent with HNE activity and are a reasonable representation of 
CtHtrA activity. Data analysis was conducted using GraphPad prism.  
4.4. Chlamydia cellular assays 
In vitro C. trachomatis and C. pecorum cell culture assays were conducted according to our 
previously reported method.19 C. trachomatis D (D/UW-3/Cx) and C. pecorum IPA (ATCC 
VR629) isolates were routinely cultured in McCoy B cells on DMEM, 10% fetal calf serum (FCS) 
at 37 °C, 5% CO2, 0.1 mg/mL streptomycin, and 0.05 mg/ml gentamycin. Inhibitor experiments 
were routinely conducted in 96-well plates seeded with 20,000 host cells per well 24 h prior to the 
Chlamydial infection. Infections were routinely conducted at a Multiplicity of Infection (MOI) of 
0.3. The Inclusion Forming Units (IFU) were determined from cultures harvested at the completion 
of the developmental cycle during which inhibitor treatment was conducted. Briefly, JO146 and 
its analogues at 50 µM, 100 µM and 10 µM doses alongside a DMSO control (inhibitor solvent), 
were added at 16 h post infection (PI) and left in the cultures until completion of the developmental 
cycle (44 h PI). Harvested cultures were lysed by vigorous pipetting and serially diluted onto fresh 
monolayers, fixed and stained for enumeration of IFU/ml. Results obtained from these experiments 
are presented in tables S1 and S2 in the supporting information. 
4.5 Docking 
Docking was carried out using GOLD v5.2 with a previously built homology model of CtHtrA.38-
39 The ligands (14a and 14c) were prepared and docked based on mechanisms described by 
previous X-ray crystal structures of α-ketoheterocycles covalently bound to serine proteases.21, 40 
Key hydrogen bonding constraints between the enzyme and ligands were pre-defined. These 
included a covalent bond between the carbonyl carbon alpha to the heterocycles and the catalytic 
serine hydroxyl oxygen forming a covalent hemiketal adduct, hydrogen bond between NH of P1 
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amide and C=O of Thr263 and another hydrogen bond between C=O of P1 backbone and NH of 
Ile265 amide.  
Abbreviations 
CtHtrA, Chlamydia trachomatis high temperature requirement A protease; SAR, structure activity 
relationship; HBTU, O-(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate; 
HPLC, high pressure liquid chromatography; DIEA, N,N-diisopropylethylamine; DMF, 
dimethylformamide; DMP, Dess-Martin periodinane; TFA, trifluoroacetic acid; IFU, inclusion 
forming unit; Val, valine; Tle, tertiary leucine; Pro, proline; Ile, isoleucine; Nva, norvaline; TLC, 
thin layer chromatography; Cbz, Carboxybenzyl; Cpr, cyclopropyl; PI, post infection; DMSO, 
dimethyl sulphoxide; MCA, 7-methoxycoumarin-4-acetic acid. 
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Figure Captions 
Figure 1. Structures of JO146 (1) and JCP83 (2) and the P3-P1 protease nomenclature.
18 TSA – 
Transition State Analogue. 
Figure 2 C. trachomatis susceptibility to representative inhibitors (100 µM, 16 h PI) of different 
covalent and noncovalent transition state analogues during mid-replicative phase of the 
pathogen’s developmental cycle. Inclusion forming units counts (IFU/mL) were determined 
upon completion of developmental cycle. Green (P3 variants); brown (P1 variants); purple (α-
ketoheterocyclic variants); beige (α-diketone variants); light blue and lilac (P3 and P1 variants); 
grey (P3 and P1 α-ketoheterocycle). Error bars indicate the standard error of the mean obtained 
from experimental replicates (minimum of 5).*Note in this assay 103 is the threshold for detect 
and can be equivalent to too few to accurately quantify. 
Figure 3: Susceptibility of C. pecorum to CtHtrA inhibitors (100 µM; 16 h PI) during mid-
replicative phase of the pathogen’s developmental cycle. Infectious yield counts (IFU/mL) were 
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determined upon completion of developmental cycle. Colours the same as above in Figure 2. 
Error bars indicate the standard error of the mean obtained from experimental replicates 
(minimum of 5). 
Figure 4. Binding poses of 14c, magenta (A) and 14a, cyan (B) to CtHtrA (transparent surface). 
Oxygen is shown in red, nitrogen blue and sulphur in yellow. 
 
 
